Wound dressing

Information

  • Patent Grant
  • 11458044
  • Patent Number
    11,458,044
  • Date Filed
    Monday, September 24, 2018
    5 years ago
  • Date Issued
    Tuesday, October 4, 2022
    a year ago
Abstract
A wound dressing including a nonwoven absorbent layer including a layer of fabric comprising gel-forming fibers. The absorbent layer is gathered in a longitudinal direction by stitching through the layer of fabric using one or more resilient threads or yarns and an inelastic thread or yarn. The resilient and inelastic threads or yarns gather the layer of fabric so that the layer of fabric in use is configured to maintain close conformability with a wound during movement, and to elongate by 35% to 85% and then recover.
Description

This invention relates to a wound dressing, in particular to wound dressings for use on post surgical sites. The invention preferably relates to dressings comprising gel forming fibres used on sites requiring a high degree of conformability and resilience such as those on the hip or knee following orthopaedic surgery.


Wounds on post operative sites such as those following knee or hip surgery can suffer problems with blistering of the skin around the incision site and infection. In addition frequent dressing changes may be necessary due to copious discharge produced at the site.


It is known to use carboxymethylated cellulosic materials in situations where a high degree of exudate absorption is required. For example, WO 93/12275 describes the production of various absorbent products capable of absorbing many times their own weight of water. This causes the carboxymethylated fibres to form a gel. WO 94/16746 and WO 00/01425 describe the use of carboxymethylated Lyocell materials in wound dressings where the advantages of gel formation in preventing adherence and therefore reducing wound damage and pain on removal are discussed.


It is also known to use carboxymethylated cellulosic fibres in the form of a fabric in combination with an adhesive layer to treat post surgical sites. For example, it is known to use Aquacel® (a dressing made of carboxymethylated cellulosic fibres and sold by ConvaTec) combined with Duoderm® Extra Thin® (an occlusive exterior layer which is also adhesive) on post surgical sites in a method reported as the Jubilee method where an Aquacel® island in the form of a narrow strip is surrounded at its periphery with an overlying layer of Duoderm Extra Thin which secures the dressing to the site (The Jubilee Method: a modern dressing design which reduces complications and is cost-effective following total knee and hip arthroplasty. Dillon J. M., Clarke, J. V. et al. Dept of Orthopaedics, Golden Jubilee National Hospital Glasgow EWMA2007, Glasgow).


Although such a combination of advanced dressing materials provides advances over a traditional gauze dressing in that for instance blistering and infection are reduced, post surgical sites have specific needs that remain to be addressed. For instance, dressings for use on the knee or hip following arthroplasty or those on sites where there is a wide range of patient movement require high conformability and resilience from the dressing otherwise patient movement is restricted and blistering occurs due to friction between the dressing and the skin. Most absorbent pads are unable to stretch and so delaminate on flexion of the knee or joint. Even gel-forming dressings break down with repeated movement of the limb. The non-woven fabric of Aquacel®, although conformable and flexible can tend to shrink on absorption of exudate making it less able to bend and stretch. It would be desirable to bring the advantages of gel forming dressings to surgical sites by having the dressings available in a form with a reduced tendency to shrink and an ability for all the layers to stretch and recover so that the dressing accommodates the normal movement of the joint during wear.


It is known to increase the tensile strength of bandages by stitching the bandage longitudinally with one or more lines of stitches. WO 2007/003905 describes such dressings which are particularly suitable for use in dressing burns.


We have found that it is possible to improve the resilience of dressings to mitigate the problems associated with dressing post operative sites where movement occurs.


Accordingly the invention provides a wound dressing comprising an absorbent layer, the absorbent layer being gathered in a longitudinal direction by one or more resilient yarns.


By resilient is meant that the yarn or thread is able to extend and contract to its former shape. The gathers in the absorbent layer formed by the resilient thread or yarn, enable the absorbent layer to extend and contract with movement so that when, for example, the patient's leg is bent the dressing stretches and when the leg is straightened, the dressing recovers its former size. This resilience means that the absorbent layer maintains close conformability with the wound during movement of the patient. It also means that the dressing has a reduced tendency to delaminate during wear. Having the ability to stretch means that there is less movement between the dressing and the patient which reduces blistering.


Preferably the dressing further comprises an adhesive layer overlying the absorbent layer on a surface furthest from the wound in use and extending beyond the periphery of the absorbent layer so as to secure the dressing to the skin.


Preferably the absorbent layer further comprises lines of longitudinal warp stitches formed from an inelastic thread which stitching is longitudinal in that it is generally parallel to the long dimension of the absorbent layer. The warp stitches are preferably made in the absorbent layer after it has been formed.


The inelastic warp stitching preferably passes through the whole thickness of the absorbent layer and is visible on both sides. The absorbent layer preferably comprises two or more layers of fabric that are layered together and stitch bonded with lines of longitudinal inelastic warp stitches. The resilient thread is preferably woven in between the stitches of the inelastic warp stitching and in between the sheets of fabric. By having two layers of fabric it is possible to hold the resilient thread or yarn out of direct contact with the wound.


The resilient thread gathers the absorbent layer and enables it to elongate and then return to shape. The resilient thread can be stitched through the absorbent layer to gather the dressing or woven through a separate line of inelastic warp stitches. The resilient thread can be stitched through the absorbent layer in lines of longitudinal stitches 1 mm to 10 mm apart, more preferably 2 mm to 5 mm apart. The resilient thread is preferably applied to the absorbent layer after the absorbent layer has been formed.


The absorbent layer preferably has an absorbency of at least 2 grams of of 0.9% saline solution per gram of fabric as measured by the free swell method. The absorbent layer preferably comprises gel forming fibres. By gel forming is meant hygroscopic fibres which upon the uptake of wound exudate become moist slippery or gelatinous and thus reduce the tendancy for the surrounding fibres to adhere to the wound. The gel forming fibres can be of the type which retain their structural integrity on absorption of exudate or can be of the type which lose their fibrous form and become a structureless gel. The gel forming fibres are preferably spun sodium carboxymethylcellulose fibres, chemically modified cellulosic fibres, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres, or other polysaccharide fibres or fibres derived from gums. The cellulosic fibres preferably have a degree of substitution of at least 0.05 carboxymethyl groups per glucose unit. The gel forming fibres preferably have an absorbency of at least 2 grams 0.9% saline solution per gram of fibre (as measured by the free swell method).


Preferably the gel forming fibres have an absorbency of at least 10 g/g as measured in the free swell absorbency method, more preferably, between 15 g/g and 25 g/g.


Carboxymethylation can be achieved, for example, by sequential or simultaneous treatment of the cellulosic material with a strong alkali, such as aqueous sodium hydroxide, and monochloroacetic acid or a salt thereof. The appropriate reaction conditions will depend upon the composition of the fabric and the degree of carboxymethylation required and will be readily apparent to the person skilled in the art. They may be identical or similar to those described in WO 93/12275, WO 94/16746 or WO 00/01425 to which the reader is directed for further detail.


Desirably the carboxymethylation is carried out in the presence of industrial methylated spirits (IMS), and IMS is preferably also used in a subsequent washing step, suitably along with water, as a cleaner and steriliser. The degree of carboxymethylation is desirably such that upon absorption of exudate the fibres at the skin-contacting surface of the bandage form a gel.


The dressing may for instance comprise non gel forming fibres and in particular may comprise Linel, Lycra® or other elastic fibre.


The dressing may be in the form of a rectangle and be available in the following sizes, 9 cm×10 cm, 9 cm×15 cm, 9 cm×25 cm, 9 cm×35 cm. The lines of inelastic warp stitching may be from 1 mm to 10 mm apart and preferably from 2 mm to 5 mm apart. The lines of inelastic stitching are typically crocheted or knitted and have the appearance of a chain stitch but other stitch patterns may also be used. Preferably, the lines of resilient stitching gather the absorbent layer so that the absorbent layer is able to elongate by 25% to 85%, more preferably 35% to 75% and most preferably 40% to 70% and then recover even when the absorbent layer is hydrated. More preferably, the lines of warp stitching are made in a yarn or thread such as nylon or polyester or Tencel™ or any thread which is strong and easily processed. The resilient stitches are made in a resilient yarn such as an elastomeric yarn or linel or Lycra® or yarn which has good stretch and recovery or an elastane yarn which is an elastomeric yarn with greater than 85% polyurethane such as linel or Lycra® or Spandex.


The dressing may comprise a further adhesive layer overlying the first adhesive layer but on the opposite side of the absorbent layer. Preferably the adhesive layer includes a reinforcing scrim of polyurethane film to reduce any tendency of the adhesive to delaminate on dressing removal. The further adhesive layer preferably has a window cut from it that coincides with the absorbent layer and is present to hold the absorbent layer within the dressing and enable direct contact between the absorbent layer and the wound.


The adhesive layer may be of the type comprising a homogenous blend of one or more water soluble hydrocolloids and one or more low molecular weight polyisobutylenes such as are described in EP-B-92999 incorporated herein by reference. The water soluble hydrocolloids may be selected from sodium carboxymethylcellulose, pectin, gelatine, guar gum, locust bean gum, karaya gum, and mixtures thereof. The polyisobutylenes may be selected from low molecular weight polyisobutylenes having a viscosity average molecular weight of from 36,000 to 58,000 (Florey). The adhesive layer is capable of absorbing exudate while maintaining adhesion of the dressing to the skin.


Alternatively the adhesive composition may comprise a homogeneous blend of one or more hydrocolloids, one or more low molecular weight polyisobutylenes, one or more styrene block copolymers, mineral oil, butyl rubber, a tackifier and small amounts of optional components. By selection of specific ranges of the amounts of the above listed components, an adhesive composition may be prepared having good adhesion to the skin and stretchability. Such compositions and the preparation therefore are disclosed in EP-B-130061.


Preferably the adhesive is such that the removal of an adhesive wound dressing is not traumatic to the patient. Preferably the adhesive ensures a secure application of the dressing whist still permitting non-traumatic removal. Non-traumatic dressing removal may be facilitated by using an adhesive which gels slightly upon interaction with a fluid. The gel formation aiding dressing removal.


The absorbent layer may comprise one or more medicaments. For example an antimicrobial agent, or an antibiotic, or an anaesthetic on an anti-inflammatory agent or a skin protective agent or an odour absorbing agent.


In a further aspect the invention provides a method of manufacturing a wound dressing for use on post surgical wounds characterised in that the method comprises the steps of:

    • (i) forming an absorbent layer; and
    • (ii) gathering the absorbent layer with a resilient yarn.


Preferably the absorbent layer is formed first and is then stitched with a resilient yarn to gather it. The absorbent layer is preferably a layer of non woven gel forming fibres which is first formed and then stitch bonded with an inelastic yarn and a resilient yarn to gather it.





Preferred embodiments of the invention will now be described with reference to the accompanying drawings in which:



FIG. 1 is a view of a preferred embodiment of the dressing according to the invention in perspective view; and



FIG. 2 is an exploded view of a further embodiment of the dressing according to the invention in perspective.





In FIG. 1 the dressing comprises a layer of hydrocolloid adhesive 2 onto which is bonded an absorbent layer 4. A further layer 6 of hydrocolloid adhesive having a window 8 is applied over the absorbent layer so that the absorbent layer is sandwiched between the two adhesive layers with the window exposing the absorbent layer to the surgical site.


The absorbent layer is made from a non woven roll made by forming a web of Lyocell which is then hydroentangled. The web is then carboxymethylated by sequential or simultaneous treatment of the cellulosic material with a strong alkali, monochloroacetic acid or a salt thereof. Two webs of the resulting fabric are then fed into a stitch bonding machine and stitched simultaneously with lines of longitudinal stitching in an inelastic yarn and a resilient yarn woven in between the stitches and so secured at the centre of the webs. The resilient yarn gathers the absorbent layer (not shown) and is carried by the inelastic stitch bonded yarn. The resulting layer has a basis weight of 350 gm−2.


In FIG. 2 the dressing comprises two layers of hydrocolloid adhesive 10, 12 reinforced by a polyurethane film 14 into which is cut a window 16. An absorbent layer 18 is positioned over the window and overlaps the adhesive layer around its margin. A further layer 20 of adhesive backed with a polyurethane film is applied over the absorbent layer so that the absorbent layer is sandwiched between the layers with the window 16 exposing the absorbent layer 18 to the surgical site.


The absorbent layer is made from a tow of carboxymethyl cellulose filaments which has been needlefelted. Two webs of the needlefelted tow are fed into a stitch bonding machine and stitched simultaneously with lines of longitudinal stitching as shown in FIG. 2 in inelastic yarn and with a resilient yarn woven inbetween the stitches and so secured at the centre of the webs.


In the context of the present invention the terms yarn and thread are used to interchangeably.


Preferred embodiments of the invention will now be described with reference to the following examples:


EXAMPLE 1

The absorbency of the dressing described in FIG. 1 was measured against the absorbency of a dressing used in the Jubilee method referenced above. The absorbencies of the dressings were measured using the method described in BS EN 13726-1:2002 Test Methods for Primary Wound Dressings—Part 1: Aspects of absorbency.


The results are shown below:
















Control, Jubilee




method (4 layers of



Aquacel and



DuoDerm Extra Thin)
Dressing of FIG. 1


















Fluid absorbed by
6.3 (5.9-6.8)
6.9 (6.8-7.0)


dressing(g/10 cm2) (24 hr)


Fluid handling capacity
6.6 (6.2-7.2)
7.4 (7.3-7.5)


(g/10 cm2) (24 hr)









These results show that the dressing according to the invention with a gathered absorbent layer has an absorbency and fluid handling capacity equivalent to that of a dressing using four layers of the same absorbent material.


EXAMPLE 2

The resilience of the dressing of FIG. 1 was measured by hydrating the dressing with 30 ml of solution A which was coloured using blue food dye. Masking tape was adhered to the short ends of the dressing and the dressing fixed in the grips of a Zwick Universal Testing Machine. The distance between the grips was extended by 20% and the Zwick was set to run a cyclic test with a pause at maximum extension of 15 seconds and a pause at recovery of 60 seconds. The number of cycles was 1000 with a speed of travel of 250 mm per minute. After testing no breakdown of the dressing was seen. The dressing remained integral and retained all of the solution A added at the beginning of the test. The force required to extend a 25 cm dressing length was 10.76 N. The stretch as a percentage of the original dressing length was 20%.


These results suggest that the dressing may enable increased or easier limb movement during patient rehabilitation.

Claims
  • 1. A wound dressing comprising a nonwoven absorbent layer comprising a layer of fabric comprising gel-forming fibers, the absorbent layer being gathered in a longitudinal direction by stitching through the layer of fabric using one or more resilient threads or yarns and an inelastic thread or yarn, wherein the resilient and inelastic threads or yarns extend at least primarily in the longitudinal direction, and wherein the resilient and inelastic threads or yarns gather the layer of fabric so that the layer of fabric in use is configured to: (a) maintain close conformability with a wound during movement; and(b) elongate by 35% to 85% and then recover.
  • 2. The wound dressing as claimed in claim 1 further comprising an adhesive layer overlying the absorbent layer on a surface furthest from the wound in use and extending beyond a periphery of the absorbent layer so as to secure the dressing to skin surrounding the wound.
  • 3. The wound dressing as claimed in claim 1 characterised in that the resilient thread or yarn is woven in between the inelastic thread or yarn stitches to gather the absorbent layer.
  • 4. The wound dressing of claim 1, wherein the layer of fabric is configured to fully recover after an elongation in the range of 35% to 85%.
  • 5. The wound dressing of claim 1, wherein the gel-forming fibers are configured to retain structural integrity on absorption of exudate.
  • 6. The wound dressing of claim 1, wherein the gel-forming fibers are configured to lose fibrous form and become a structureless gel upon absorption of exudate.
  • 7. The wound dressing of claim 1, further comprising an inelastic warp stitch formed of the inelastic thread or yarn.
  • 8. The wound dressing of claim 7, wherein the inelastic warp stitch extends in the longitudinal direction.
  • 9. The wound dressing of claim 7, wherein the inelastic warp stitch passes through an entire thickness of the absorbent layer such that a first portion of the inelastic warp stitch is positioned on a first side of the absorbent layer and a second portion of the inelastic warp stitch is positioned on an opposite second side of the absorbent layer.
  • 10. The wound dressing of claim 1, wherein the resilient and inelastic threads or yarns are parallel to one another.
  • 11. A method of manufacturing the wound dressing of claim 1, wherein the method comprises the steps of: (i) forming the nonwoven absorbent layer comprising the layer of fabric comprising gel-forming fibers; and(ii) gathering the absorbent layer by stitching through the layer of fabric with the resilient thread or yarn and the inelastic thread or yarn, wherein the resilient and inelastic threads or yarns gather the layer of fabric so that the layer of fabric in use is configured to: (a) maintain close conformability with a wound during movement; and(b) elongate by 35% to 85% and then recover.
  • 12. The method as claimed in claim 11 characterised in that the absorbent layer is formed from a non-woven fabric.
  • 13. The method as claimed in claim 12 characterised in that the method comprises the further step of simultaneously weaving the resilient thread or yarn about the stitches of inelastic thread or yarn.
  • 14. The method as claimed in claim 11, further comprising: (iii) overlying the absorbent layer with an adhesive layer on a surface furthest from the wound in use and extending beyond the periphery of the absorbent layer so as to adhere the dressing to the skin.
  • 15. A wound dressing, comprising: a nonwoven absorbent layer comprising a layer of fabric comprising gel-forming fibers; andstitching that extends through the absorbent layer and that gathers the absorbent layer in a longitudinal direction, wherein the stitching comprises: a resilient thread or yarn extending at least primarily in the longitudinal direction; andan inelastic thread or yarn extending at least primarily in the longitudinal direction;wherein the stitching gathers the layer of fabric such that the layer of fabric is configured to: maintain close conformability with a wound during movement; andelongate from an initial length by 35% to 85% and to thereafter recover to the initial length.
  • 16. The wound dressing of claim 15, further comprising an adhesive layer overlying the absorbent layer and extending beyond a periphery of the absorbent layer.
  • 17. The wound dressing of claim 15, wherein the gel-forming fibers are configured to retain structural integrity on absorption of exudate.
  • 18. The wound dressing of claim 15, wherein the gel-forming fibers are configured to lose fibrous form and become a structureless gel upon absorption of exudate.
  • 19. The wound dressing of claim 15, wherein the resilient thread or yarn is parallel to the inelastic thread or yarn.
Priority Claims (1)
Number Date Country Kind
0817796 Sep 2008 GB national
CROSS-REFERENCE

This application is a continuation of U.S. application Ser. No. 13/120,733, filed Aug. 8, 2011, which is the U.S. National Stage Entry of International Application No. PCT/GB2009/002342, filed Sep. 29, 2009, which claims priority to United Kingdom Application No. 0817796.6, filed on Sep. 29, 2008, all of which are incorporated herein by reference their entireties.

US Referenced Citations (572)
Number Name Date Kind
3367333 Scheier Feb 1968 A
4773238 Zafiroglu Sep 1988 A
4891957 Strack et al. Jan 1990 A
4957795 Riedel Sep 1990 A
5203186 Zafiroglu Apr 1993 A
5308673 Tochacek May 1994 A
5623888 Zafiroglu Apr 1997 A
5647842 Kininmonth et al. Jul 1997 A
6233795 Dischler May 2001 B1
6267744 Roberts Jul 2001 B1
6555730 Albrod Apr 2003 B1
10016537 Menon et al. Jul 2018 B2
10046096 Askem et al. Aug 2018 B2
10076447 Barta et al. Sep 2018 B2
10076587 Locke et al. Sep 2018 B2
10117783 Cotton Nov 2018 B2
10143784 Walton et al. Dec 2018 B2
10426670 Von Blucher et al. Oct 2019 B2
10426747 Johnson Oct 2019 B2
10426874 Chien et al. Oct 2019 B2
10426875 Blott et al. Oct 2019 B2
10426938 Locke et al. Oct 2019 B2
10434015 Taylor et al. Oct 2019 B2
10434142 Niazi et al. Oct 2019 B2
10434210 Olson et al. Oct 2019 B2
10434284 Hanson et al. Oct 2019 B2
10449094 Donda et al. Oct 2019 B2
D866756 Allen et al. Nov 2019 S
10463760 Karthikeyan et al. Nov 2019 B2
10463773 Haggstrom et al. Nov 2019 B2
10470933 Riesinger Nov 2019 B2
10470936 Wohlgemuth et al. Nov 2019 B2
10471122 Shi et al. Nov 2019 B2
10471190 Locke et al. Nov 2019 B2
10478345 Barta et al. Nov 2019 B2
10478346 Knutson Nov 2019 B2
10478394 Yu Nov 2019 B2
10485707 Sexton Nov 2019 B2
10485891 Andrews et al. Nov 2019 B2
10485892 Hands et al. Nov 2019 B2
10485906 Freedman et al. Nov 2019 B2
10486135 Yang et al. Nov 2019 B2
10492956 Zamierowski Dec 2019 B2
10493178 Marchant et al. Dec 2019 B2
10493184 Collinson et al. Dec 2019 B2
10493185 Stokes et al. Dec 2019 B2
10500099 Hung et al. Dec 2019 B2
10500103 Croizat et al. Dec 2019 B2
10500104 Sookraj Dec 2019 B2
10500173 Yang et al. Dec 2019 B2
10500235 Wardell Dec 2019 B2
10500300 Dybe et al. Dec 2019 B2
10500301 Laurensou Dec 2019 B2
10500302 Holm et al. Dec 2019 B2
10501487 Andrews et al. Dec 2019 B2
10506928 Locke et al. Dec 2019 B2
10507141 Allen et al. Dec 2019 B2
10507259 Cree et al. Dec 2019 B2
10512707 Whalen, III et al. Dec 2019 B2
10525170 Havenstrite et al. Jan 2020 B2
10532137 Pratt et al. Jan 2020 B2
10532194 Locke et al. Jan 2020 B2
10537657 Phillips et al. Jan 2020 B2
10542936 Goldberg et al. Jan 2020 B2
10543133 Shaw et al. Jan 2020 B2
10543293 Suschek Jan 2020 B2
10548777 Locke et al. Feb 2020 B2
10549008 Yoo Feb 2020 B2
10549016 Bushko et al. Feb 2020 B2
10549017 Hsiao et al. Feb 2020 B2
10555838 Wu et al. Feb 2020 B2
10555839 Hartwell Feb 2020 B2
10556044 Robinson et al. Feb 2020 B2
10561533 Hoggarth et al. Feb 2020 B2
10561536 Holm et al. Feb 2020 B2
10568767 Addison et al. Feb 2020 B2
10568768 Long et al. Feb 2020 B2
10568770 Robinson et al. Feb 2020 B2
10568771 MacDonald et al. Feb 2020 B2
10568773 Tuck et al. Feb 2020 B2
10568983 Gerdes et al. Feb 2020 B2
10575991 Dunn Mar 2020 B2
10575992 Sarangapani Mar 2020 B2
10576037 Harrell Mar 2020 B2
10576189 Locke et al. Mar 2020 B2
10583042 Sarangapani et al. Mar 2020 B2
10583228 Shuler et al. Mar 2020 B2
10589007 Coulthard et al. Mar 2020 B2
10590184 Kuo Mar 2020 B2
10610414 Hartwell et al. Apr 2020 B2
10610415 Griffey et al. Apr 2020 B2
10610623 Robinson et al. Apr 2020 B2
10617569 Bonn Apr 2020 B2
10617608 Shin et al. Apr 2020 B2
10617769 Huang Apr 2020 B2
10617784 Yu et al. Apr 2020 B2
10617786 Kluge et al. Apr 2020 B2
10618266 Wright et al. Apr 2020 B2
10624984 Courage et al. Apr 2020 B2
10625002 Locke et al. Apr 2020 B2
10632019 Vitaris Apr 2020 B2
10632224 Hardy et al. Apr 2020 B2
10639206 Hu et al. May 2020 B2
10639350 Arber et al. May 2020 B2
10639404 Lichtenstein May 2020 B2
10646614 Grinstaff et al. May 2020 B2
10653562 Robinson et al. May 2020 B2
10653782 Ameer et al. May 2020 B2
10653810 Datt et al. May 2020 B2
10653821 Nichols May 2020 B2
10653823 Bharti et al. May 2020 B2
10660799 Wu et al. May 2020 B2
10660851 Millis et al. May 2020 B2
10660992 Canner et al. May 2020 B2
10660994 Askem et al. May 2020 B2
10667955 Allen et al. Jun 2020 B2
10667956 Van Holten et al. Jun 2020 B2
10682257 Lu Jun 2020 B2
10682258 Manwaring et al. Jun 2020 B2
10682259 Hunt et al. Jun 2020 B2
10682318 Twomey et al. Jun 2020 B2
10682386 Ellis-Behnke et al. Jun 2020 B2
10682446 Askem et al. Jun 2020 B2
10687983 Dahlberg et al. Jun 2020 B2
10687985 Lee et al. Jun 2020 B2
10688215 Munro et al. Jun 2020 B2
10688217 Hanson et al. Jun 2020 B2
RE48117 Albert et al. Jul 2020 E
10702419 Locke et al. Jul 2020 B2
10702420 Hammond et al. Jul 2020 B2
10703942 Tunius Jul 2020 B2
10709760 Gronberg et al. Jul 2020 B2
10709807 Kshirsagar Jul 2020 B2
10709883 Spector Jul 2020 B2
10716711 Locke et al. Jul 2020 B2
10716874 Koyama et al. Jul 2020 B2
10729589 Dorian et al. Aug 2020 B2
10729590 Simmons et al. Aug 2020 B2
10729826 Lin Aug 2020 B2
10736787 Hannigan et al. Aug 2020 B2
10736788 Locke et al. Aug 2020 B2
10736985 Odermatt et al. Aug 2020 B2
10737003 Fujisaki Aug 2020 B2
10743900 Ingram et al. Aug 2020 B2
10744040 Kazala, Jr. et al. Aug 2020 B2
10744041 Hartwell Aug 2020 B2
10744225 Lindgren et al. Aug 2020 B2
10744237 Guidi et al. Aug 2020 B2
10744238 Guidi et al. Aug 2020 B2
10744239 Armstrong et al. Aug 2020 B2
10744240 Simmons et al. Aug 2020 B2
10751212 Raza et al. Aug 2020 B2
10751442 Bonnefin et al. Aug 2020 B2
10751452 Topaz Aug 2020 B2
10758423 Pigg et al. Sep 2020 B2
10758424 Blott et al. Sep 2020 B2
10758425 Blott et al. Sep 2020 B2
10758426 Eddy Sep 2020 B2
10758651 Blott et al. Sep 2020 B2
10765561 Lattimore et al. Sep 2020 B2
10765783 Locke et al. Sep 2020 B2
10772767 Bjork et al. Sep 2020 B2
10772999 Svensby Sep 2020 B2
10779993 Bishop et al. Sep 2020 B2
10780114 Udagawa et al. Sep 2020 B2
10780194 Flach et al. Sep 2020 B2
10780201 Lin Sep 2020 B2
10780202 Askem et al. Sep 2020 B2
10780203 Coulthard et al. Sep 2020 B2
10782238 Hicks et al. Sep 2020 B2
10792191 Robinson et al. Oct 2020 B2
10792192 Tout et al. Oct 2020 B2
10792337 Leung et al. Oct 2020 B2
10792404 Hu et al. Oct 2020 B2
10792482 Randolph et al. Oct 2020 B2
10800905 Delli-Santi et al. Oct 2020 B2
10806819 Shuler Oct 2020 B2
20030040691 Griesbach, III Feb 2003 A1
20050015068 Bean et al. Jan 2005 A1
20060089614 Bonnin Apr 2006 A1
20060127462 Canada et al. Jun 2006 A1
20060155260 Blott et al. Jul 2006 A1
20060172000 Cullen et al. Aug 2006 A1
20060253058 Evans Nov 2006 A1
20070042024 Gladman Feb 2007 A1
20070160654 Ferguson Jul 2007 A1
20070173162 Ethiopia et al. Jul 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070219512 Heaton et al. Sep 2007 A1
20070225663 Watt Sep 2007 A1
20070239078 Jaeb Oct 2007 A1
20090234307 Vitaris Sep 2009 A1
20090259203 Hu et al. Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299303 Seegert Dec 2009 A1
20100015208 Kershaw et al. Jan 2010 A1
20100030178 MacMeccan et al. Feb 2010 A1
20100125233 Edward S. et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100185163 Heagle Jul 2010 A1
20100298790 Guidi et al. Nov 2010 A1
20110015595 Robinson et al. Jan 2011 A1
20110028918 Hartwell Feb 2011 A1
20110112457 Holm et al. May 2011 A1
20110178451 Robinson et al. Jul 2011 A1
20110224593 Tunius Sep 2011 A1
20110224630 Simmons et al. Sep 2011 A1
20110230849 Coulthard et al. Sep 2011 A1
20110251566 Zimnitsky et al. Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110257573 Hong et al. Oct 2011 A1
20110275972 Rosenberg Nov 2011 A1
20120071845 Hu et al. Mar 2012 A1
20120130332 Cotton et al. May 2012 A1
20120136325 Allen et al. May 2012 A1
20120209226 Simmons et al. Aug 2012 A1
20130053795 Coulthard et al. Feb 2013 A1
20130123728 Pratt et al. May 2013 A1
20130226063 Taylor et al. Aug 2013 A1
20140005618 Locke et al. Jan 2014 A1
20140074053 Locke et al. Mar 2014 A1
20140188060 Robinson et al. Jul 2014 A1
20140194838 Wibaux et al. Jul 2014 A1
20140200532 Robinson et al. Jul 2014 A1
20140236112 Von Wolff et al. Aug 2014 A1
20140256925 Catchmark et al. Sep 2014 A1
20140276499 Locke et al. Sep 2014 A1
20140296804 Hicks et al. Oct 2014 A1
20140308338 Nierle et al. Oct 2014 A1
20140309574 Cotton Oct 2014 A1
20150018433 Leipzig et al. Jan 2015 A1
20150057624 Simmons et al. Feb 2015 A1
20150071985 Walker et al. Mar 2015 A1
20150079152 Wuollett et al. Mar 2015 A1
20150094674 Pratt et al. Apr 2015 A1
20150104486 Bonnefin et al. Apr 2015 A1
20150112311 Hammond et al. Apr 2015 A1
20150119831 Robinson et al. Apr 2015 A1
20150119834 Locke et al. Apr 2015 A1
20150141941 Allen et al. May 2015 A1
20150148785 Kleiner May 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150245949 Locke et al. Sep 2015 A1
20150246164 Heaton et al. Sep 2015 A1
20150250979 Loske Sep 2015 A1
20150265741 Duncan et al. Sep 2015 A1
20150265743 Hanson et al. Sep 2015 A1
20150320901 Chandrashekhar-Bhat et al. Nov 2015 A1
20160008293 Shi et al. Jan 2016 A1
20160038626 Locke et al. Feb 2016 A1
20160051724 Sahin et al. Feb 2016 A1
20160067107 Cotton Mar 2016 A1
20160100987 Hartwell et al. Apr 2016 A1
20160106878 Yang et al. Apr 2016 A1
20160106892 Hartwell Apr 2016 A1
20160166422 Karim et al. Jun 2016 A1
20160193244 Ota et al. Jul 2016 A1
20160222548 Agboh Aug 2016 A1
20160271178 Hauser et al. Sep 2016 A1
20160287743 Andrews Oct 2016 A1
20160339158 Collinson et al. Nov 2016 A1
20160374847 Lachenbruch et al. Dec 2016 A1
20170014275 Schneider Jan 2017 A1
20170049111 Patton et al. Feb 2017 A1
20170072669 Sekido et al. Mar 2017 A1
20170128269 Coulthard et al. May 2017 A1
20170189237 Locke et al. Jul 2017 A1
20170189575 Lee et al. Jul 2017 A1
20170209615 Tornero Garcia et al. Jul 2017 A1
20170232161 Fewkes et al. Aug 2017 A1
20170258956 Flach et al. Sep 2017 A1
20170367895 Holm et al. Dec 2017 A1
20170368239 Askem et al. Dec 2017 A1
20180008742 Hoggarth et al. Jan 2018 A1
20180014974 Hoggarth et al. Jan 2018 A1
20180023217 Patton et al. Jan 2018 A1
20180030321 Tunius Feb 2018 A1
20180042789 Bradford et al. Feb 2018 A1
20180078423 Magin et al. Mar 2018 A1
20180086903 Zhang et al. Mar 2018 A1
20180118809 Mearns Spragg May 2018 A1
20180133066 Ahsani et al. May 2018 A1
20180140467 Hunt May 2018 A1
20180140822 Robinson et al. May 2018 A1
20180200414 Askem et al. Jul 2018 A1
20180221531 Bender et al. Aug 2018 A1
20180236124 Young et al. Aug 2018 A1
20180243463 Chatterjee et al. Aug 2018 A1
20180243464 Hwang et al. Aug 2018 A1
20180244857 Lee et al. Aug 2018 A1
20180272052 Locke et al. Sep 2018 A1
20180296397 Askem et al. Oct 2018 A1
20180303873 Been et al. Oct 2018 A1
20180311419 Locke et al. Nov 2018 A1
20180333522 Pratt et al. Nov 2018 A1
20180344533 Rovaniemi Dec 2018 A1
20180353334 Locke et al. Dec 2018 A1
20180353337 Locke Dec 2018 A1
20180353339 Locke et al. Dec 2018 A1
20180353340 Robinson et al. Dec 2018 A1
20180353344 Locke et al. Dec 2018 A1
20180353662 Locke et al. Dec 2018 A1
20180353663 Locke et al. Dec 2018 A1
20180360667 Droche Dec 2018 A1
20190000677 Munro Jan 2019 A1
20190015258 Gowans et al. Jan 2019 A1
20190015468 Yadav et al. Jan 2019 A1
20190030223 Lin Jan 2019 A1
20190046682 Choi et al. Feb 2019 A1
20190060127 Locke et al. Feb 2019 A1
20190083752 Howell et al. Mar 2019 A1
20190117465 Osborne et al. Apr 2019 A1
20190117466 Kazala, Jr. et al. Apr 2019 A1
20190117861 Locke et al. Apr 2019 A1
20190125590 Rehbein et al. May 2019 A1
20190133830 Bishop et al. May 2019 A1
20190151155 Bonn May 2019 A1
20190151159 Gowans et al. May 2019 A1
20190151495 Helary et al. May 2019 A1
20190184052 Ilan et al. Jun 2019 A1
20190231600 Locke et al. Aug 2019 A1
20190231602 Locke et al. Aug 2019 A1
20190231943 Robinson et al. Aug 2019 A1
20190274889 Steward et al. Sep 2019 A1
20190282728 Kellar et al. Sep 2019 A1
20190290799 Arshi et al. Sep 2019 A1
20190298249 Bates et al. Oct 2019 A1
20190298577 Locke et al. Oct 2019 A1
20190298578 Shulman et al. Oct 2019 A1
20190298579 Moore et al. Oct 2019 A1
20190298580 Hall et al. Oct 2019 A1
20190298582 Addison et al. Oct 2019 A1
20190298881 Ramjit et al. Oct 2019 A1
20190298882 Nelson Oct 2019 A1
20190298895 Selby et al. Oct 2019 A1
20190307611 Askem et al. Oct 2019 A1
20190307612 Hartwell et al. Oct 2019 A1
20190307934 Allen et al. Oct 2019 A1
20190307935 Simmons et al. Oct 2019 A1
20190314187 Emslander et al. Oct 2019 A1
20190314209 Ha et al. Oct 2019 A1
20190314544 Filho et al. Oct 2019 A1
20190321232 Jardret et al. Oct 2019 A1
20190321509 Chakravarthy et al. Oct 2019 A1
20190321526 Robinson et al. Oct 2019 A1
20190322795 Kubo et al. Oct 2019 A1
20190328580 Emslander et al. Oct 2019 A1
20190336343 Etchells et al. Nov 2019 A1
20190336344 Locke Nov 2019 A1
20190336345 Bannwart Nov 2019 A1
20190336346 Locke et al. Nov 2019 A1
20190336640 Vismara et al. Nov 2019 A1
20190336641 Nisbet Nov 2019 A1
20190336643 Luukko et al. Nov 2019 A1
20190336658 Heaton et al. Nov 2019 A1
20190336739 Locke et al. Nov 2019 A1
20190343687 Locke et al. Nov 2019 A1
20190343889 Luukko et al. Nov 2019 A1
20190343979 Kearney et al. Nov 2019 A1
20190343993 Weston Nov 2019 A1
20190343994 Greener Nov 2019 A1
20190344242 Kim et al. Nov 2019 A1
20190350763 Pratt et al. Nov 2019 A1
20190350764 Zochowski et al. Nov 2019 A1
20190350765 Heagle et al. Nov 2019 A1
20190350775 Biasutti et al. Nov 2019 A1
20190350970 Saphier et al. Nov 2019 A1
20190351092 Silver et al. Nov 2019 A1
20190351093 Stein et al. Nov 2019 A1
20190351094 Maher et al. Nov 2019 A1
20190351095 Maher et al. Nov 2019 A1
20190351111 Locke et al. Nov 2019 A1
20190358088 Lavocah et al. Nov 2019 A1
20190358361 McInnes et al. Nov 2019 A1
20190358372 Askem et al. Nov 2019 A1
20190365948 Deegan et al. Dec 2019 A1
20190365962 Lee et al. Dec 2019 A1
20190374408 Robles et al. Dec 2019 A1
20190374673 Hoefinghoff et al. Dec 2019 A1
20190380878 Edwards et al. Dec 2019 A1
20190380881 Albert et al. Dec 2019 A1
20190380882 Taylor et al. Dec 2019 A1
20190380883 Macphee et al. Dec 2019 A1
20190381222 Locke et al. Dec 2019 A9
20190388577 Chandrashekhar-Bhat et al. Dec 2019 A1
20190388579 Macphee et al. Dec 2019 A1
20190388589 Macphee et al. Dec 2019 A1
20200000640 Mondal et al. Jan 2020 A1
20200000642 Waite Jan 2020 A1
20200000955 Andrews et al. Jan 2020 A1
20200000956 Huang et al. Jan 2020 A1
20200000985 Seddon et al. Jan 2020 A1
20200008981 Wheldrake Jan 2020 A1
20200009289 Torabinejad et al. Jan 2020 A1
20200009400 Ribeiro et al. Jan 2020 A1
20200017650 Young et al. Jan 2020 A1
20200022844 Blott et al. Jan 2020 A1
20200023102 Powell Jan 2020 A1
20200023103 Joshi et al. Jan 2020 A1
20200023104 Eriksson et al. Jan 2020 A1
20200023105 Long et al. Jan 2020 A1
20200023106 Carroll et al. Jan 2020 A1
20200030153 Johannison et al. Jan 2020 A1
20200030480 Choi Jan 2020 A1
20200030499 Menon et al. Jan 2020 A1
20200038023 Dunn Feb 2020 A1
20200038249 Pratt et al. Feb 2020 A1
20200038250 Edwards et al. Feb 2020 A1
20200038251 Locke et al. Feb 2020 A1
20200038252 Spiro Feb 2020 A1
20200038283 Hall et al. Feb 2020 A1
20200038470 Datt et al. Feb 2020 A1
20200038544 Grover et al. Feb 2020 A1
20200038546 Dizio et al. Feb 2020 A1
20200038639 Patel et al. Feb 2020 A1
20200046565 Barta et al. Feb 2020 A1
20200046566 Carey et al. Feb 2020 A1
20200046567 Carroll et al. Feb 2020 A1
20200046568 Sexton Feb 2020 A1
20200046663 Murdock et al. Feb 2020 A1
20200046876 Liu Feb 2020 A1
20200046887 Runquist et al. Feb 2020 A1
20200054491 Hentrich et al. Feb 2020 A1
20200054781 Weiser et al. Feb 2020 A1
20200060879 Edwards et al. Feb 2020 A1
20200061253 Long et al. Feb 2020 A1
20200061254 Joshi et al. Feb 2020 A1
20200061379 Bogie et al. Feb 2020 A1
20200064220 Locke Feb 2020 A1
20200069183 Rice et al. Mar 2020 A1
20200069476 Randolph et al. Mar 2020 A1
20200069477 Holm et al. Mar 2020 A1
20200069478 Jabbarzadeh et al. Mar 2020 A1
20200069479 Buan et al. Mar 2020 A1
20200069835 Hissink et al. Mar 2020 A1
20200069850 Beadle et al. Mar 2020 A1
20200069851 Blott et al. Mar 2020 A1
20200069853 Hall et al. Mar 2020 A1
20200078223 Locke et al. Mar 2020 A1
20200078224 Carroll et al. Mar 2020 A1
20200078225 Grillitsch et al. Mar 2020 A1
20200078305 Auvinen et al. Mar 2020 A1
20200078330 Gay Mar 2020 A1
20200078482 Yoon et al. Mar 2020 A1
20200078499 Gadde et al. Mar 2020 A1
20200085625 Bellini et al. Mar 2020 A1
20200085626 Braga et al. Mar 2020 A1
20200085629 Locke et al. Mar 2020 A1
20200085630 Robinson et al. Mar 2020 A1
20200085632 Locke et al. Mar 2020 A1
20200085991 Coomber Mar 2020 A1
20200085992 Locke et al. Mar 2020 A1
20200086014 Locke et al. Mar 2020 A1
20200086017 Jardret et al. Mar 2020 A1
20200086049 Park et al. Mar 2020 A1
20200093646 Locke et al. Mar 2020 A1
20200093756 Sabacinski Mar 2020 A1
20200093953 Kim et al. Mar 2020 A1
20200093954 Leise, III Mar 2020 A1
20200093970 Hunt et al. Mar 2020 A1
20200095421 Kettel Mar 2020 A1
20200095620 Kellar et al. Mar 2020 A1
20200100945 Albert et al. Apr 2020 A1
20200107964 Locke et al. Apr 2020 A1
20200107965 Greener Apr 2020 A1
20200107967 Holm et al. Apr 2020 A1
20200108169 Hu et al. Apr 2020 A1
20200113741 Rehbein et al. Apr 2020 A1
20200114039 Wang et al. Apr 2020 A1
20200114040 Waite et al. Apr 2020 A1
20200114049 Wall Apr 2020 A1
20200121510 Hartwell et al. Apr 2020 A1
20200121521 Daniel et al. Apr 2020 A1
20200121833 Askem et al. Apr 2020 A9
20200129338 Gardiner et al. Apr 2020 A1
20200129341 Coulthard et al. Apr 2020 A1
20200129654 Bouvier et al. Apr 2020 A1
20200129655 Gardiner et al. Apr 2020 A1
20200129675 Robinson et al. Apr 2020 A1
20200138754 Johnson May 2020 A1
20200139023 Haggstrom et al. May 2020 A1
20200139025 Robinson et al. May 2020 A1
20200141031 Kosan et al. May 2020 A1
20200146894 Long et al. May 2020 A1
20200155355 Hill et al. May 2020 A1
20200155358 Wheldrake May 2020 A1
20200155361 Pigg et al. May 2020 A1
20200155379 Shaw et al. May 2020 A1
20200163802 Hunt et al. May 2020 A1
20200163803 Pigg et al. May 2020 A1
20200164112 Kato et al. May 2020 A1
20200164120 Jaecklein et al. May 2020 A1
20200170841 Waite et al. Jun 2020 A1
20200170842 Locke Jun 2020 A1
20200170843 Collinson et al. Jun 2020 A1
20200171197 Hubbell et al. Jun 2020 A1
20200179558 Munro et al. Jun 2020 A1
20200179673 Wan Jun 2020 A1
20200188180 Akbari et al. Jun 2020 A1
20200188182 Sanders et al. Jun 2020 A1
20200188550 Dagger et al. Jun 2020 A1
20200188564 Dunn Jun 2020 A1
20200190310 Meyer Jun 2020 A1
20200197227 Locke et al. Jun 2020 A1
20200197228 Hartwell Jun 2020 A1
20200197559 Bourdillon et al. Jun 2020 A1
20200197580 Kilpadi et al. Jun 2020 A1
20200206036 Robinson et al. Jul 2020 A1
20200214637 Brownhill et al. Jul 2020 A1
20200214897 Long et al. Jul 2020 A1
20200214898 Waite et al. Jul 2020 A1
20200215220 Schomburg et al. Jul 2020 A1
20200215226 Kitagawa et al. Jul 2020 A1
20200222469 Cotton Jul 2020 A1
20200229983 Robinson et al. Jul 2020 A1
20200237564 Hammond et al. Jul 2020 A1
20200237816 Lait Jul 2020 A1
20200246195 Robinson et al. Aug 2020 A1
20200253785 Bernet et al. Aug 2020 A1
20200253786 Harrison et al. Aug 2020 A1
20200254139 Phillips et al. Aug 2020 A1
20200261275 Manwaring et al. Aug 2020 A1
20200261276 Lujan Hernandez et al. Aug 2020 A1
20200268560 Harrison et al. Aug 2020 A1
20200268561 Locke et al. Aug 2020 A1
20200270484 Lipscomb et al. Aug 2020 A1
20200276055 Randolph et al. Sep 2020 A1
20200276058 Locke et al. Sep 2020 A1
20200277450 Silverstein et al. Sep 2020 A1
20200281519 Gowans et al. Sep 2020 A1
20200281529 Grubb et al. Sep 2020 A1
20200281678 Long et al. Sep 2020 A1
20200281775 Kushnir et al. Sep 2020 A1
20200282100 Gil et al. Sep 2020 A1
20200282114 Long et al. Sep 2020 A1
20200282115 Gardner et al. Sep 2020 A1
20200289328 Luckemeyer et al. Sep 2020 A1
20200289347 Gowans et al. Sep 2020 A1
20200289701 Hall et al. Sep 2020 A1
20200289712 Jiang et al. Sep 2020 A1
20200289723 Gregory Sep 2020 A1
20200289726 Locke et al. Sep 2020 A1
20200289727 Locke Sep 2020 A1
20200289806 Locke et al. Sep 2020 A1
20200297541 Hartwell et al. Sep 2020 A1
20200297543 Rodzewicz et al. Sep 2020 A1
20200297544 Moine et al. Sep 2020 A1
20200297892 Silcock Sep 2020 A1
20200297893 Ericson Sep 2020 A1
20200297894 Koyama et al. Sep 2020 A1
20200299865 Bonnefin et al. Sep 2020 A1
20200306089 Delury et al. Oct 2020 A1
20200306091 Lee et al. Oct 2020 A1
20200306094 Kushnir et al. Oct 2020 A1
20200315853 Waite Oct 2020 A1
20200315854 Simmons et al. Oct 2020 A1
20200316271 Lin Oct 2020 A1
20200323692 Locke et al. Oct 2020 A1
20200324015 Kettel et al. Oct 2020 A1
20200330283 Locke et al. Oct 2020 A1
20200330284 Locke et al. Oct 2020 A1
20200330285 Rehbein et al. Oct 2020 A1
20200330658 Fujisaki Oct 2020 A1
20200330660 Patel et al. Oct 2020 A1
20200337719 Ingram et al. Oct 2020 A1
20200337904 Waite Oct 2020 A1
20200337905 Earl et al. Oct 2020 A1
20200337906 Long et al. Oct 2020 A1
20200337908 Long et al. Oct 2020 A1
20200338228 Kharkar et al. Oct 2020 A1
20200338243 Harrison et al. Oct 2020 A1
Foreign Referenced Citations (82)
Number Date Country
0130061 Aug 1988 EP
0092999 Apr 1992 EP
3187204 Jul 2017 EP
738722 Oct 1955 GB
WO-9312275 Jun 1993 WO
WO-9416746 Aug 1994 WO
WO-0001425 Jan 2000 WO
2005018543 Mar 2005 WO
WO-2007003905 Jan 2007 WO
2011121394 Oct 2011 WO
2011135284 Nov 2011 WO
2011144888 Nov 2011 WO
2013015827 Jan 2013 WO
2013126049 Aug 2013 WO
2014014842 Jan 2014 WO
2015145117 Oct 2015 WO
2015173546 Nov 2015 WO
2016141450 Sep 2016 WO
2017016974 Feb 2017 WO
2017125250 Jul 2017 WO
2018029231 Feb 2018 WO
2018094061 May 2018 WO
2018162613 Sep 2018 WO
2018163093 Sep 2018 WO
2018189265 Oct 2018 WO
2018226667 Dec 2018 WO
2018227144 Dec 2018 WO
2018231825 Dec 2018 WO
2018236648 Dec 2018 WO
2019002085 Jan 2019 WO
2019012068 Jan 2019 WO
2019012069 Jan 2019 WO
2019022493 Jan 2019 WO
2019027933 Feb 2019 WO
2019038548 Feb 2019 WO
2019038549 Feb 2019 WO
2019040656 Feb 2019 WO
2019050855 Mar 2019 WO
2019058373 Mar 2019 WO
2019073326 Apr 2019 WO
2019083563 May 2019 WO
2019083868 May 2019 WO
2019086911 May 2019 WO
2019091150 May 2019 WO
2019094147 May 2019 WO
2019096828 May 2019 WO
2019113275 Jun 2019 WO
2019113623 Jun 2019 WO
2019191590 Oct 2019 WO
2019193141 Oct 2019 WO
2019193333 Oct 2019 WO
2019199389 Oct 2019 WO
2019199596 Oct 2019 WO
2019199687 Oct 2019 WO
2019199798 Oct 2019 WO
2019199849 Oct 2019 WO
2019200035 Oct 2019 WO
2019215572 Nov 2019 WO
2019219613 Nov 2019 WO
2019234365 Dec 2019 WO
2020005062 Jan 2020 WO
2020005344 Jan 2020 WO
2020005536 Jan 2020 WO
2020005546 Jan 2020 WO
2020005577 Jan 2020 WO
2020007429 Jan 2020 WO
2020011691 Jan 2020 WO
2020014178 Jan 2020 WO
2020014310 Jan 2020 WO
2020018300 Jan 2020 WO
2020026061 Feb 2020 WO
2020026144 Feb 2020 WO
2020033351 Feb 2020 WO
2020035811 Feb 2020 WO
2020043665 Mar 2020 WO
2020044237 Mar 2020 WO
2020046443 Mar 2020 WO
2020047255 Mar 2020 WO
2020049038 Mar 2020 WO
2020055945 Mar 2020 WO
2020056182 Mar 2020 WO
2020056914 Mar 2020 WO
Non-Patent Literature Citations (9)
Entry
Structure, 2017, The George Washington University Museum The Textile Museum (Year: 2017).
Dillon, J.M. et al. The Jubilee method a modern dressing design which reduces complications and improves cost-effectiveness following total hip and knee arthroplasty. 8th European Federation of National Associations of Orthopaedics and Traumatology Congress, May 11, 2007. Glaslow.
No Author. BS EN 13726-1: 2002 Test Methods for Primary Wound Dressings Part 1: Aspects of absorbency, (pp. 1-20) (Apr. 15, 2002).
U.S. Appl. No. 13/120,733 Office Action dated Jun. 1, 2017.
U.S. Appl. No. 13/120,733 Office Action dated Mar. 22, 2016.
U.S. Appl. No. 13/120,733 Office Action dated Nov. 17, 2016.
U.S. Appl. No. 13/120,733 Office Action dated Nov. 8, 2017.
White, Sarah E. Yarn Over, About Home. http://knitting.about.com./od/knittingglossary/g/yarn_over.htm (Oct. 29, 2007).
Worst, Edward. Problems in Raffia. Industrial Education. Volume 8. CCM Professional Magazines, Inc. 1919, p. 183.
Related Publications (1)
Number Date Country
20190021912 A1 Jan 2019 US
Continuations (1)
Number Date Country
Parent 13120733 US
Child 16140438 US